Navigation Links
Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial
Date:3/25/2009

ung and ovarian cancers that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The primary objective of the trial was to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN when administered in combination with gemcitabine. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

Gemzar(R) is indicated for NSCLC, breast, pancreatic and ovarian cancer. For more information about Gemzar(R), please visit www.gemzar.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. and U.S. combination REOLYSIN/gemcitabine clinical trials and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue researc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Reovirus Research at Replicating Oncolytic Virus Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial
3. Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
4. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
5. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
7. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
8. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
9. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Research and Markets has announced the addition ... Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - ... The global molecular biology enzymes market was ... to grow at a CAGR of 13.74% to reach ... reagents find applications in a large number of fields ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 The ... model organisms can be accelerated by exome sequencing. ... manufacturing technologies, the custom SeqCap EZ Developer system ... , Mr. Watson will additionally present how he ... commercially available human and mouse exome kits. With ...
(Date:8/21/2014)... 21, 2014 DNA vaccine pioneer ... its development of JRC-LAMP-vax, an innovative and safe potential ... IC studies began this month in Hawaii, moving the ... , The Japanese red cedar releases pollen that causes ... Mountain Cedar pollen wreaks similar havoc in Colorado, New ...
(Date:8/21/2014)... August 21, 2014 2014 ... Industryā€¯ is a professional and in-depth research ... report provides basic Seaweed Fertilizer information, including ... chain structure as well as industry overview. ... including domestic market as well as global ...
Breaking Biology Technology:Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3
... GE Healthcare said it has installed its first volume ... be used exclusively by a cardiologist. , ,Round Rock Cardiology ... patients' hearts and nearby arteries. GE said the scans take ... 64 images, LightSpeed builds up a three-dimensional view. , ,The ...
... Thompson, former U.S. Health and Human Services secretary and ... executive positions since leaving his Cabinet post in January. ... Four accounting firm Deloitte & Touche USA; law partner ... Feld; and president of La Crosse-based Logistics Health Inc., ...
... office just recently and we didn't hire him. , ,It was a ... when he came to the interview: "Tell us what you know about ... just now, I am excited to learn more." A big, silent gong ... a prospective employer for anyone to fail to do so. Midwest technology ...
Cached Biology Technology:Tommy Thompson tackles the private sector in spades 2Hone your pre-interview skills or you may lose that tech job 2Hone your pre-interview skills or you may lose that tech job 3Hone your pre-interview skills or you may lose that tech job 4Hone your pre-interview skills or you may lose that tech job 5
(Date:8/22/2014)... is available in French . ... essential nutrients from African soils looming as a major threat ... today finds that over the last five years, 1.7 million ... have rejuvenated 1.6 million hectares and helped them double or ... for a Green Revolution in Africa (AGRA) focuses on intensive ...
(Date:8/22/2014)... Bethesda, MD FASEB MARC (Maximizing Access to Research ... the FASEB Grant Writing Seminar & Practical Exercises Workshop ... in Bethesda, Maryland from August 25-26, 2014. These ... postdoctorates and research scientists from underrepresented groups in the ... This year MARC conferred 11 awards totaling $20,350. ...
(Date:8/22/2014)... discoveries in basic and clinical research and technological ... a complex offensive spanning multiple fronts. , Work ... could help find new and more selective therapies ... targets a specific enzyme overexpressed in certain cancersand ... brain tumours. , Chemistry professor Christopher Cairo and ...
Breaking Biology News(10 mins):Effort to confront Africa's soil health crisis helps millions of farmers triple yields 2Effort to confront Africa's soil health crisis helps millions of farmers triple yields 3Effort to confront Africa's soil health crisis helps millions of farmers triple yields 4New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3
... international research consortium has sequenced the genome of the ... Dec. 26 advance online edition of the journal ... possibilities for breeding tastier, hardier varieties of the berry ... the strawberry parts list," said the consortium,s leader Kevin ...
... COLLEGE PARK, Md. The latest success of Martek ... a decade ago in a plain, brick building on ... and early-stage nurturing from the university,s Maryland Technology Enterprise ... into a major international business. On December ...
... University of Arizona researchers may have found a way ... doses without harming healthy body cells. If successful, ... effective to destroy cancer cells and alleviate the harmful ... The invention by Marek Romanowski, an associate professor of ...
Cached Biology News:Georgia Tech team helps decode newly sequenced strawberry genome 2Georgia Tech team helps decode newly sequenced strawberry genome 3Tech firm joins the 'billion dollar club' -- with university help 2Tech firm joins the 'billion dollar club' -- with university help 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 2Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 3Invention could improve cancer drug delivery, lessen harmful effects of chemotherapy 4
...
... Deacetylase (HDAC) Antibody Sampler Kit Kit ... Catalog #2062, 40 ul Histone Deacetylase 3 ... Deacetylase 4 (HDAC4) Antibody, Catalog #2072, 40 ... #2082, 40 ul Histone Deacetylase 6 (HDAC6) ...
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: